SCHEMBL29469703

SCHEMBL29469703

CCOc1ccccc1S(=O)(=O)NC(=O)c1cc2c(F)cc(N3CCC3CNC(=O)OC)cc2o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
ACHE P22303 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HTT P42858 2/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
ALOX5 P09917 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
USP2 O75604 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 1/20 0.33
RORC P51449 1/20 0.33
TSHR P16473 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24334420 1.00 ALDH1A1 (0.36) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL24333740 0.88 TP53 (0.37) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL29469902 0.88 TP53 (0.37) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL29469629 0.86 ALDH1A1 (0.39) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL24334384 0.86 ALDH1A1 (0.39) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL29469645 0.86 TP53 (0.36) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL24334385 0.86 ALDH1A1 (0.39) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL24334282 0.86 TP53 (0.36) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL24333707 0.86 RORC (0.36) ALDH1A1HPGDTP53ACHEMEN1
SCHEMBL29469652 0.86 RORC (0.36) ALDH1A1HPGDTP53ACHEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US claimed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 EP claimed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO claimed
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US disclosed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 EP disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A ALDH1A1 985/4885HPGD 3209/4885TP53 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.